rss
Br J Ophthalmol 2005;89:113-119 doi:10.1136/bjo.2004.043075
  • Laboratory science - Extended reports

Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris

  1. T A Ciulla1,
  2. M H Criswell1,
  3. W J Snyder2,
  4. W Small IV2
  1. 1Retina Service Research Laboratories, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA
  2. 2Miravant Medical Technologies Inc., Santa Barbara, CA, USA
  1. Correspondence to: Thomas A Ciulla MD Macula-Retina-Vitreous Section, Midwest Eye Institute, 201 Pennsylvania Parkway, Indianapolis, IN 46280, USA; thomasciullayahoo.com
  • Accepted 2 June 2004

Abstract

Aim: The new photosensitiser PhotoPoint MV6401, indium chloride methyl pyropheophorbide, was assessed as a possible ocular photodynamic therapy agent in a rat model of experimentally induced corneal neovascularisation and in choriocapillaris closure in the rabbit. Optimal drug and light activation parameters were determined.

Methods: MV6401 (Miravant Pharmaceuticals, Inc, Santa Barbara, CA, USA) was activated at 664 nm using a DD3-0665 (Miravant Systems Inc) 0.5 W diode laser. Corneal neovascularisation in rats was induced using an N-heptanol technique. The evaluated drug dosages, light dosages, and post-injection activation times ranged from 0.01–0.1 μmol/kg, 5–25 J/cm2, and 10–60 minutes, respectively. The efficacy of MV6401 on normal choriocapillaris and choroidal vessels was evaluated in rabbits with indirect ophthalmoscopy, fundus photography, fluorescein angiography, and histology. In rabbits, the evaluated drug dosages, light dosages, and post-injection activation times ranged from 0.025–0.25 μmol/kg, 3.3–20 J/cm2, and 10 minutes, respectively.

Results: In the rat corneal neovascularisation model, an optimal intravenous drug dosage of 0.075 μmol/kg was activated by a 20 J/cm2 light dose at 10 minutes after drug administration, the results of which demonstrated early evidence of efficacy in ocular neovascularisation. In rabbits, closure of the normal choriocapillaris was selectively achieved at a drug dosage of 0.15 μmol/kg using light doses from 3.3 to 20 J/cm2.

Conclusion: PhotoPoint MV6401 is a potent photosensitiser that demonstrates both efficacy and selectivity in experimental ocular models.

Footnotes

  • Supported by National Eye Institute Grant R44 EY11191, Business Innovation Research Program via Miravant Medical Technologies, by a grant from Miravant Medical Technologies Inc, and by an unrestricted grant from Research to Prevent Blindness, Inc, New York. TA Ciulla is a recipient of a Career Development Award from Research to Prevent Blindness, Inc, New York, USA.

  • Proprietary interest: Drs Snyder and Small are employees of Miravant Medical Technologies Inc.

  • This research investigation was performed at both locations.

  • PhotoPoint is a trademark of Miravant Medical Technologies, Santa Barbara, CA, USA.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.